期刊
ANNALS OF ONCOLOGY
卷 20, 期 11, 页码 1818-1823出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdp209
关键词
chemotherapy; p53; pRb; prognosis; triple-negative breast cancer
类别
资金
- Pallotti's Legacy for Cancer Research
- MIUR
- Centro Interdipartimentale per la Ricerca sul Cancro Giorgio Prodi'', University of Bologna
Patients and methods: pRb status was prospectively evaluated by immunocytochemistry in 518 consecutive patients with complete receptor information. The predictive value of pRb status in TNBCs was determined according to the adjuvant therapeutic treatments. Results: Fifty-three tumors were identified as TNBCs. The prevalence of pRb loss was significantly higher in TNBCs than in the other cancer subtypes. All patients with TNBCs lacking pRb and treated with systemic chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil) were disease free at a medium follow-up time of 109 months, whereas the clinical outcome of those expressing pRb was significantly poorer (P = 0.008). Analysis of disease-free survival including the established anatomo-clinical prognostic parameters indicated pRb loss as the only significant predictive factor. Conclusions: pRb loss is much more frequent in TNBCs than in the other breast cancer subtypes. Patients with TNBCs lacking pRb had a very favorable clinical outcome if treated with conventional adjuvant chemotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据